Drug Profile
Research programme: CTLA-4/FasL fusion protein - KAHR Medical
Alternative Names: KAHR-102Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator KAHR Medical
- Class Antineoplastics; Proteins
- Mechanism of Action Apoptosis stimulants; CD80 antigen inhibitors; CD86 antigen inhibitors; CD95 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Lymphoma
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Lymphoma in Israel
- 11 Apr 2018 Preclinical trials in Lymphoma in Israel (unspecified route) (KAHR Medical pipeline, April 2018)
- 11 Apr 2018 KAHR Medical plans clinical evaluation of KAHR 102 for Lymphoma, in 2019 (KAHR Medical pipeline, April 2018)